Market Overview

ISIS Pharmaceuticals, Inc. (ISIS) Maintains A Buy Rating


Analysts Mark Monane, and Alan Carr at Needham have release an update on ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS).

The company along with its partner Genzyme Corporation (NASDAQ: GENZ) reported top-line results for Phase 3 mipomersen trial in patients with heterozygous familial hypercholesterolemia already on lipid-lowering agents.

According to analysts, the efficacy results from the trial are clinically meaningful. Analysts at Needham have reiterated a Buy rating for ISIS Pharmaceuticals, Inc., with a 12-month price target of $22.

According to analysts, ISIS’s net cash position, high-quality collaborations with big brand names in Pharma, and upcoming pipeline events are additional resources beyond mipomersen at the company.


Related Articles (GENZ + ISIS)

View Comments and Join the Discussion!

Posted-In: Alan Carr Mark Monane NeedhamAnalyst Color News Markets Analyst Ratings

Latest Ratings

JBLRBC CapitalMaintains38.0
COSTRBC CapitalMaintains412.0
COSTMKM PartnersMaintains325.0
MTNTruist SecuritiesMaintains243.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at